Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 30, 2015
Pharmacy Choice - Pharmacy News - March 30, 2015

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
3/30/15 - Boston Scientific announces FDA and CE Mark Approval Of The EMBLEMâ?¢ S-ICD System
By a News Reporter-Staff News Editor at Biotech Business Week-- Boston Scientific Corporation has received FDA and CE Mark approval of the EMBLEMâ?¢ Subcutaneous Implantable Defibrillator System. A controlled and limited market release has begun in a small number of European centers with a broad European launch scheduled for May 2015 and subsequent
3/30/15 - Boston Scientific Receives FDA Approval for WATCHMANâ?¢ Left Atrial Appendage Closure Device
By a News Reporter-Staff News Editor at Biotech Business Week-- Boston Scientific Corporation has received U.S. Food and Drug Administration approval for the WATCHMAN Left Atrial Appendage Closure Device. "The WATCHMAN Device is an important step forward in stroke management for patients with AF," said Vivek Reddy, M.D., Director of the Cardiac Ar
3/30/15 - CHOLBAM cholic acid Now Approved In The U.S. For Patients With Bile Acid Synthesis Disorders
By a News Reporter-Staff News Editor at Pharma Business Week-- Asklepion Pharmaceuticals, LLC. announced that the U.S. Food and Drug Administration approved CHOLBAMâ?¢ as a once-daily treatment for cholic acid deficiency in bile acid synthesis disorders due to single enzyme defects. CHOLBAM is the first medication approved by the FDA to turn off a.
3/30/15 - Just Approved By FDA, New Ground Breaking Procedure for Heart Rhythm Patients
By a News Reporter-Staff News Editor at Pharma Business Week-- The Arizona Heart Rhythm Center will be the only medical facility in Arizona with access to a new device developed to lower the risk of stroke in patients with an irregular heartbeat who require blood thinning medications. The device, called the Watchman ® Left Atrial Appendage Closure
3/30/15 - Kalorama: 23andMe FDA Approval Clears Way for More Sequencing-Based Tests
By a News Reporter-Staff News Editor at Biotech Business Week--- Kalorama information suggests that the FDA approval of a rare gene test from Mountain View, Calif.- based personal genetics company 23 andMe will open the way for more genetic tests sold to consumers or prescribed by doctors that use next-generation sequencing technology. A Feb. 19 ap
3/30/15 - Semler Announces FDA Clearance for Next Generation PAD Testing System
By a News Reporter-Staff News Editor at Pharma Business Week-- Semler Scientific, Inc., an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, announced receipt of 510 marketing clearance from the U.S. Food and Dru

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415